Fate Therapeutics, Inc. News Releases https://ir.fatetherapeutics.com/ Fate Therapeutics, Inc. News Releases en Fate Therapeutics Reports First Quarter 2019 Financial Results and Highlights Operational Progress https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-reports-first-quarter-2019-financial-results First-ever Patient Treated in U.S. with an iPSC-derived Cell Therapy Successfully Advances through Six-dose Treatment Course No Dose-Limiting Toxicities or Serious Adverse Events Reported in Initial Cohort of FT500 iPSC-derived NK Cell Cancer Immunotherapy Patients FT500 Clinical Trial Now Open for Tue, 07 May 2019 16:01:00 -0400 Fate Therapeutics, Inc. News Releases 10426 Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2019 Financial Results https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-webcast-conference-call-reporting-first-4 SAN DIEGO , April 30, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and Tue, 30 Apr 2019 16:05:00 -0400 Fate Therapeutics, Inc. News Releases 10411 Fate Therapeutics Announces Five Presentations at the American Society of Gene & Cell Therapy 22nd Annual Meeting https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-announces-five-presentations-american-society SAN DIEGO , April 24, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Fate scientists and collaborators will present Wed, 24 Apr 2019 08:00:00 -0400 Fate Therapeutics, Inc. News Releases 10401 Fate Therapeutics Appoints Wayne Chu, M.D. as Vice President, Clinical Development https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-appoints-wayne-chu-md-vice-president-clinical SAN DIEGO , April 18, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Yu-Waye (Wayne) Chu , M.D. Thu, 18 Apr 2019 08:01:00 -0400 Fate Therapeutics, Inc. News Releases 10391 Fate Therapeutics Announces First Patient Treated with iPSC-derived NK Cell Cancer Immunotherapy FT500 Successfully Completes Initial Safety Assessment https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-announces-first-patient-treated-ipsc-derived No Dose-Limiting Toxicities or Serious Adverse Events Reported following Three Once Weekly Doses of Universal, Off-the-Shelf NK Cell Product Candidate New Preclinical Data of Universal, Off-the-shelf, iPSC-derived NK Cell Product Candidates FT516 and FT596 Highlighted at 2019 AACR Annual Meeting Tue, 02 Apr 2019 08:00:00 -0400 Fate Therapeutics, Inc. News Releases 10381 Fate Therapeutics Presents Late-Breaking Preclinical Data Highlighting Unique Advantages of Clonal Master Engineered iPSC Lines for Off-the-Shelf CAR T-cell Therapy at 2019 AACR Annual Meeting https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-presents-late-breaking-preclinical-data High-Throughput Selection of a Single Gene-Edited iPSC Enables Mass Production of Uniformly Engineered CAR T Cells FT819 Off-the-Shelf CAR19 T-cell Product Candidate Demonstrates Complete Elimination of TCR Expression and Integration of Novel 1XX CAR into TRAC Locus SAN DIEGO, Calif. Mon, 01 Apr 2019 08:01:00 -0400 Fate Therapeutics, Inc. News Releases 10376 Fate Therapeutics Announces the Appointment of Karin Jooss, Ph.D. to its Board of Directors https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-announces-appointment-karin-jooss-phd-its SAN DIEGO , March 18, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Karin Jooss , Ph.D. Mon, 18 Mar 2019 08:00:00 -0400 Fate Therapeutics, Inc. News Releases 10336 Fate Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-reports-fourth-quarter-and-full-year-2018 First Patient Treated with FT500 Off-the-Shelf NK Cell Cancer Immunotherapy in Landmark Clinical Trial Marks First-ever Human Administration of iPSC-derived Cell Therapy in the United States $201 Million in Cash & Short-term Investments as of December 31, 2018 SAN DIEGO , March 05, 2019 (GLOBE Tue, 05 Mar 2019 16:01:00 -0500 Fate Therapeutics, Inc. News Releases 10316 Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2018 Financial Results https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-webcast-conference-call-reporting-fourth-4 SAN DIEGO , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Thu, 28 Feb 2019 16:43:00 -0500 Fate Therapeutics, Inc. News Releases 10291 Fate Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-present-8th-annual-svb-leerink-global SAN DIEGO , Feb. 22, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko , President and Chief Executive Fri, 22 Feb 2019 08:00:00 -0500 Fate Therapeutics, Inc. News Releases 10276